Introduction
============

Generic drugs account for nearly nine out of every 10 prescriptions filled in the US and the UK.[@ref1] [@ref2] Generic drugs have identical active ingredients to their branded counterparts, but can be substantially less expensive.[@ref3] Owing to this lower cost, generic drugs have the potential to improve medication adherence and persistence.[@ref4] [@ref5] Generic drug products are approved when pharmaceutical equivalence and bioequivalence to the reference product have been demonstrated. No requirements for testing clinical equivalence in pre-marketing trials is required, but robust evidence from multiple post-marketing studies has demonstrated equivalent clinical efficacy of many generic drug products with their branded counterparts.[@ref4] [@ref6] [@ref7] [@ref8] [@ref9] Many patients perceive generic drug products to be less effective and less safe,[@ref10] [@ref11] [@ref12] [@ref13] and express lower confidence in them for treating serious illness.[@ref14] As a result of the negative expectations, some patients may report experiencing negative outcomes upon switching from branded to generic drug products; a phenomenon described as the nocebo effect.[@ref15]

Changes in the physical appearance of a drug product, including its shape, color, and size, may influence such negative perceptions in patients switched from branded to generic drug products and may ultimately lead patients to specifically request the brand version.[@ref16] Among patients switched from branded to generic drug products, the rates of switching back to branded drug products are reported to be in the range of 12% to 65% for many drug classes including antiepileptics, antipsychotics, and β blockers.[@ref17] [@ref18] [@ref19] Switching back to the branded drug product when low cost generic drug products are available has important economic implications for the healthcare system. Use of branded drug products when generic drug products are available increases patient expenses by an estimated \$1.2bn (£860m; €980m), and overall healthcare system costs by an estimated \$7.7bn (£5.5bn; €6.3bn) annually in the US.[@ref20] The higher costs of branded drug products can result in lower adherence which, in turn, can lead to worse clinical outcomes.[@ref4] Therefore, it is critical to carefully understand and address the reasons for switchbacks.

Authorized generic drug products are a unique type of generic drug product; they are identical in composition and appearance to the branded drug product but are marketed by the brand manufacturer (or its licensees) as generics, usually around the date of market entry of other generic drug products. Unlike other generic products, authorized generics are marketed in the US under the branded drug product's New Drug Application license without any bioequivalence testing requirements.[@ref21] As authorized generics have identical active ingredients, appearance, and excipients as the corresponding branded products, they may be less susceptible to negative perceptions that affect the use of other generic products. We hypothesized that branded to authorized generic drug product switching would be associated with fewer switchbacks compared with branded to generic drug product switching. To test this hypothesis, we compared branded to authorized generic with branded to generic drug product switchback rates in a large commercial health plan and replicated the study with data from Medicaid, a public insurance program for Americans on low incomes.

Methods
=======

Data sources
------------

The study used de-identified data from a large US commercial health insurance database from 2004-13. This source contains comprehensive longitudinal health insurance claims information on enrollee demographics, inpatient and outpatient diagnoses and procedures, and outpatient prescription dispensing records.

Drug products
-------------

In collaboration with members of the US Food and Drug Administration (FDA) Office of Generic Drugs, we screened 22 drug products that had marketed authorized generics between 2004 and 2013. We excluded products for two reasons. First, if the date of market entry of authorized generics was more than 30 days after the date of market entry of the first generic product. Concurrent availability of an authorized generic and a generic product was required to reliably evaluate switching patterns among prevalent branded drug product users (two products excluded). Second, if we were note able to definitively identify authorized generic products using current National Drug Codes (NDC) derived from the FDA NDC directory. Authorized generic, generic, and branded drug products were identified based on the Market Category Name field of the NDC directory. As the NDC directory does not maintain details on discontinued NDC, we excluded drug products for which more than 5% of filled prescriptions identified in our database belonged to NDC that were not found in the NDC directory (12 products excluded). The following eight products met our inclusion criteria: alendronate tablets, amlodipine tablets, amlodipine-benazepril capsules, calcitonin salmon nasal spray, escitalopram tablets, glipizide extended release tablets,quinapril tablets, and sertraline tablets.

Study design
------------

### Substitution analysis

We first conducted a prescription level substitution analysis to understand trends in the use of authorized generic and generic drug products in the first two years after loss of patent protection for each of the eight branded drug products included in this study. [Figure 1](#f1){ref-type="fig"} shows that we calculated the proportion of prescriptions that were filled with authorized generic, generic, and branded drug products by using 30 day intervals starting from the date of market entry of the first generic drug product.
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### Switchback analysis

We next evaluated rates of switchback to the branded drug product among patients taking branded drug products who were switched to an authorized generic or generic after their date of market entry. For this patient level analysis, we identified patients actively using branded drug products on the date of market entry of the first generic drug product for each of the eight study drug products. We defined active branded drug product users as patients filling a prescription for a branded drug product with sufficient supply to overlap with the date of market entry of generic drug products. Among branded drug product users, we identified two groups of patients. Patients in one group were switched to the same dose of an authorized generic drug product. Patients in the other group were switched to the same dose of a generic drug product. To define switches, we required the patients to be using the branded drug product without a gap of more than 14 days between the end of the last branded drug product prescription fill and the switch to authorized generic or generic drug product. [Figure 2](#f2){ref-type="fig"} shows that we followed patients who had switched to authorized generic and generic drug products beginning on this switch date to evaluate the date that they switched back to the branded drug product (outcome date). Patients who disenrolled from their health plan, changed exposure groups (switched from authorized generic to generic or vice versa), discontinued use of the drug product (defined as a gap of more than 14 days between two prescriptions), or had 365 days of follow-up data were censored.
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Statistical analysis
--------------------

We plotted proportions of prescriptions dispensed as authorized generic, generic, or branded drug products in the substitution analysis. We reported the total number of switchers included in the switchback analysis along with descriptive statistics for patient demographics stratified by switch to authorized generic or generic drug product. Unadjusted incidence rates of brand switchbacks were reported for all eight drug products and incidence rate ratios and incidence rate differences were calculated comparing branded to authorized generic with branded to generic switchers. Kaplan-Meier survival probabilities for the outcome of switchback over the follow-up time were calculated for all drug products and plotted for branded to authorized generic and branded to generic switchers along with 95% confidence intervals. We used a Cox proportional hazards regression model, adjusting for basic demographics (age, sex, and calendar year), to estimate hazard ratios and 95% confidence intervals for branded drug product switchbacks comparing branded to authorized generic with branded to generic switchers. To summarize switchback estimates across the eight study drug products, we conducted inverse variance weighted random effects meta-analyses. We quantified the between study heterogeneity with the I^2^ statistic. We used RevMan version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) for meta-analyses. All other statistical analyses were conducted with SAS version 9.4 (SAS Institute, Cary, NC).

Replication analysis
--------------------

To confirm the findings observed in our switchback analysis, we replicated our study in a separate patient population with data from Medicaid. We used Medicaid Analytic eXtract files from 49 state Medicaid programs (all states except Arizona) for the period 2000-10. Medicaid Analytic eXtract files contain comprehensive information on patient demographics, inpatient and outpatient diagnoses and procedures, and outpatient prescription dispensing records, which can be tracked longitudinally. Methods for cohort identification and statistical analysis were identical to the primary analysis. We did not include escitalopram tablets in the replication analysis because the date of market entry of generic drug products was March 2012.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

Results
=======

Substitution analysis
---------------------

[Figure 3](#f3){ref-type="fig"} shows that for all but one study drug product (calcitonin nasal spray), authorized generic and generic drug products represented a majority of drug use within the six months after the date of market entry of generic drug products. For most study drug products, the authorized generic gained and maintained substantial market share for the first two years. For alendronate tablets and escitalopram tablets, however, authorized generic utilization decreased substantially after the first nine months of generic availability. For calcitonin salmon nasal spray and amlodipine-benazepril capsules, the brand product retained a sizable market share in the first two years after authorized generic and generic drug products became available.
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Switchback analysis
-------------------

A total of 94 909 branded to authorized generic and 116 017 branded to generic switchers for seven drug products contributed to the switchback analysis. The sample size for calcitonin salmon nasal spray was insufficient to calculate switchback rates. [Table 1](#tbl1){ref-type="table"} shows that baseline demographics, including age and sex, were similar between authorized generic switchers for most of the drug products with a few exceptions. Patients switching from branded to authorized generic drug products compared with patients switching from branded to generic drug products had an older mean age for amlodipine tablets and glipizide extended release tablets and a younger mean age for sertraline tablets.

###### 

Demographic characteristics of the patients included in the study

  Drug product                         Total             Mean age, years (SD)             \% Male                            
  ------------------------------------ -------- -------- ---------------------- --------- --------- ------- -- ------ ------ ------
  Alendronate tablets                  4367     15 676                          63 (10)   63 (10)   −4.4       7.9    8.1    −0.7
  Amlodipine tablets                   26 529   31 867                          60 (12)   56 (11)   29.5       55.5   55.1   0.7
  Amlodipine-benazepril capsules       1645     20 689                          57 (10)   56 (11)   5.2        64.4   63.7   1.5
  Calcitonin salmon nasal spray        86       248                             68 (11)   69 (10)   −9.5       7.0    8.1    −4.1
  Escitalopram tablets                 24 128   5595                            47 (15)   46 (15)   2.1        31.9   31.1   1.8
  Glipizide extended release tablets   7963     6114                            59 (11)   57 (11)   19.1       58.6   58.4   0.4
  Quinapril tablets                    8799     11 165                          58 (11)   56 (11)   7.1        60.4   59.2   2.5
  Sertraline tablets                   21 478   24 911                          44 (14)   47 (15)   −15.9      30.1   29.8   0.6

Standardized difference of 10 or higher indicate meaningful differences between groups

A total of 3416 switchback events over 46 218 person years of follow-up were observed among branded to authorized generic switchers and 5336 events over 60 198 person years were observed among branded to generic switchers across the seven included drug products. Unadjusted incidence rates of switchback varied across drug products, ranging from a low of 3.8 per 100 person years for alendronate tablets to a high of 17.8 per 100 person years for amlodipine-benazepril capsules. The overall unadjusted incidence rate was 8.2 per 100 person years for the seven drug products included in this analysis. [Table 2](#tbl2){ref-type="table"} provides the unadjusted switchback rates stratified by authorized generic status for all drugs. The crude rates of switchback were noticeably lower for branded to authorized generic switchers compared with branded to generic switchers for all drug products except alendronate tablets (for which the rates were numerically lower but statistically non-significant). Incidence rate differences in switchbacks between branded to authorized generic switchers and branded to generic switchers varied from a low of 0.7 per 100 person years for alendronate tablets to a high of 5.4 per 100 person years for amlodipine-benazepril capsules. The overall incidence rate difference was 1.5 per 100 person years.

###### 

Unadjusted incidence rates of branded drug product switchbacks for authorized generic compared with generic switchers per 100 person years of follow-up

  Drug product                         Overall (95% CI)      Authorized generic switchers (95% CI)   Generic switchers (95% CI)   Incidence rate difference (95% CI)   Incidence rate ratios (95% CI)
  ------------------------------------ --------------------- --------------------------------------- ---------------------------- ------------------------------------ --------------------------------
  Alendronate tablets                  3.8 (3.4 to 4.2)      3.2 (2.4 to 4.2)                        3.9 (3.5 to 4.3)             −0.7 (−1.7 to 0.3)                   0.82 (0.61 to 1.10)
  Amlodipine tablets                   4.8 (4.6 to 5.1)      4.3 (4.0 to 4.7)                        5.2 (4.9 to 5.6)             −0.9 (−1.4 to −0.4)                  0.83 (0.75 to 0.92)
  Amlodipine-benazepril capsules       17.8 (17.0 to 18.6)   12.8 (10.6 to 15.4)                     18.3 (17.4 to 19.1)          −5.4 (−7.9 to −3.0)                  0.70 (0.58 to 0.84)
  Escitalopram tablets                 13.8 (13.2 to 14.5)   13.4 (12.7 to 14.1)                     15.6 (14.1 to 17.2)          −2.2 (−3.9 to −0.5)                  0.86 (0.77 to 0.96)
  Glipizide extended release tablets   7.8 (7.1 to 8.5)      6.5 (5.7 to 7.3)                        9.5 (8.4 to 10.7)            −3.0 (−4.4 to −1.7)                  0.68 (0.57 to 0.81)
  Quinapril tablets                    4.7 (4.4 to 5.2)      3.2 (2.7 to 3.7)                        6.0 (5.5 to 6.7)             −2.9 (−3.7 to −2.1)                  0.52 (0.43 to 0.63)
  Sertraline tablets                   9.2 (8.8 to 9.6)      8.1 (7.5 to 8.7)                        10.1 (9.5 to 10.7)           −2.0 (−2.8 to −1.2)                  0.80 (0.73 to 0.88)
  Overall                              8.2 (8.1 to 8.4)      7.4 (7.2 to 7.6)                        8.9 (8.6 to 9.1)             −1.5 (−1.8 to −1.1)                  0.83 (0.80 to 0.87)

[Figure 4](#f4){ref-type="fig"} shows Kaplan-Meier plots for all included drug products. Visual inspection of the plots indicated a sharp decline in the survival probabilities within the first three months for all drug products. This suggests that the majority of switchbacks occur soon after the switch from branded to approved generic or generic drug products. Separation of the probability curves for authorized generic and generic groups also appeared to occur within the first three months of follow-up, after which the curves were parallel.
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[Figure 5](#f5){ref-type="fig"} shows that in the adjusted analysis, the switchback rates remained consistently lower among branded to authorized generic switchers than branded to generic switchers for all included drug products. The magnitude of this effect was largest for quinapril tablets (hazard ratio 0.52, 95% confidence interval 0.43 to 0.63) and smallest for escitalopram tablets (0.86, 0.77 to 0.97). The pooled hazard ratio across the seven drug products in the study suggested that branded to authorized generic switching was associated with a 28% lower rate of switchback compared with branded to generic switching (0.72, 0.64 to 0.81). Although we observed between study heterogeneity (I^2^=77%), all hazard ratios for the individual drug products were less than 1.0 with 95% confidence intervals that excluded the null value.
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Replication analysis
--------------------

A total of 85 260 branded to authorized generic switchers and 94 372 branded to generic switchers were included in the replication analysis. Adjusted switchback rates were likewise consistently lower for branded to authorized generic switchers compared with branded to generic switchers. The differences were statistically significant for alendronate tablets, amlodipine tablets, amlodipine-benazepril capsules, and glipizide extended release tablets and non-significant for quinapril tablets and sertraline tablets. [Figure 6](#f6){ref-type="fig"} shows that the pooled hazard ratio across the six drug products included in this analysis was 0.75 (95% confidence interval 0.62 to 0.91).
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Discussion
==========

In this observational cohort study, we found that authorized generic versions of the eight study drug products were regularly dispensed during the first two years after the date of market entry of the first generic drug product. Patients who switched from branded products to authorized generic drug products upon market entry of the first generic were less likely to switchback to the branded drug product compared with patients who switched to generic drug products.

We observed that eight out of every 100 patients taking branded drug products who switched to a generic, switched back to the branded drug product within a year. The switchback rates were 28% lower for patients who switched to an authorized generic compared with patients who switched to a generic drug product. One potential reason for lower switchbacks among branded to authorized generic switchers may be the similarity in product appearance between authorized generics and branded drug products. Changes in drug product appearance upon branded to generic drug product switch may induce the nocebo effect, defined as negative effects in treatment efficacy or tolerability mediated by negative expectations, through psychological or neurobiological factors.[@ref15] [@ref22] [@ref23] A recent study purportedly tested the safety and efficacy of β blockers, but all 60 patients actually received placebos. The patients who were randomized to switch from a 'branded' to a 'generic' drug product with a different color tablet were reported to have lower reductions in blood pressure and more adverse events compared with patients who continued receiving 'branded' drug products.[@ref16] Studies have also found an association between changes in tablet appearance, including shape and color, and medication non-persistence.[@ref24] [@ref25]

Another possible explanation for higher branded switchback rates among branded to generic drug product switchers may be lower efficacy or an increase in adverse events with generic products. However, recent randomized trials of certain antiepileptic drugs have found no clinical impact of switching from branded to generic drug products.[@ref26] [@ref27] Generic drug products for various drug classes including β blockers, diuretics, calcium channel blockers, statins, and antiplatelet agents have also repeatedly been demonstrated to provide equivalent clinical benefits in short term endpoints, including blood pressure changes, urine output, and platelet aggregation as well as long term endpoints such as atherothrombotic events and healthcare utilization (eg, hospital stays and emergency department visits).[@ref4] [@ref6] [@ref7] [@ref8] [@ref28] In a separate study, we found no differences in clinically important long term outcomes between authorized generic and generic versions of all the eight drug products included in this study.[@ref29] Considering all of this available evidence suggesting similarity in clinical outcomes between independent generic products and their branded counterparts, differences observed in the switchback rates in this study between authorized generic and generic drug products are unlikely to be fully explained by differences in quality, safety, or efficacy.

One previous study of nearly 6000 switchers from a regional healthcare delivery system in the US reported the overall switchback rate of 4.8% (a total of 264 switchback events) and did not detect differences in switchback rates between authorized generic and generic switchers.[@ref30] The most likely explanations of the apparently divergent finding may include a lack of statistical power in the previous study and different individual products investigated in the two studies. Switchback patterns may depend substantially on the specific drug product factors including the total number of generics available, specific indications and formulations, marketing of specific products, and different contracting agreements between manufacturers and pharmacy chains.

Implications for policy makers
------------------------------

In the US, laws allowing for pharmacist substitution of branded drug products with generic drug products are intended to promote cost savings.[@ref31] Doctors or patients may request pharmacists to 'dispense as written' so that the branded drug product is dispensed instead of the generic drug product. According to one estimate, this practice increases the cost burden on the US healthcare system by \$7.7bn (£5.5bn; €6.3bn) annually.[@ref20] Promoting continued use of generic drug products, rather than switching back to branded drug products, could lead to substantial cost savings. One possible way to reduce switchbacks could be for generic drug products to mirror the appearance of branded drug products. Courts would likely not allow brand name manufacturers to claim intellectual property protections over their products' appearance to prevent their use by generic manufacturers.[@ref32] Additionally, doctors or pharmacists could discuss the nocebo effect with patients. Reducing switchbacks to branded drug products may be possible if patients are made aware that branded and generic drug products are of equal quality, safety, and efficacy.

Strengths and weaknesses of this study
--------------------------------------

Our study is the largest investigation to date of brand switchbacks among patients who switched from branded to authorized generic or branded to generic drug products. A major strength of this analysis is the availability of comprehensive data on prescription dispensing in two large cohorts based on national insurance programs in the US. This allowed us to document representative utilization patterns of different versions of drug products after patent expiration of the branded drug product. We consistently observed lower switchback rates among branded to authorized generic drug product switchers for seven drug products in four therapeutic classes in two separate databases, suggesting that our results are generalizable. Nevertheless, there are some limitations of this study worth discussing. First, administrative claims data are well suited to characterize patterns of drug utilization in routine clinical care (eg, substitution and switchback analysis) but do not contain information on the reasons behind an individual's decision to switch treatments or explicit information regarding patient or provider perceptions of generic drug products. Therefore, our analysis is unable to distinguish between differences in actual clinical experiences with authorized generics or generics and differences in perceptions of these products. Second, no narrow therapeutic index drugs, which have generated particular concern over generic safety and efficacy, met our inclusion criteria. Our results may therefore not generalize to these types of drugs.

Conclusions
-----------

Among patients taking branded drug products who switched to generic drug products, switchbacks occurred frequently. Patients who switched to authorized generic drug products, which have the same active ingredients, appearance, and excipients, had lower rates of switchbacks compared with patients who switched to generic drug products, which may have a different appearance and excipients compared with the branded drug product. Given that authorized generic and generic drug products have identical active ingredients, our results indicate that the higher switchbacks observed among generic switchers may in part be driven by negative perceptions of generic drug products. Interventions to reduce switchbacks may provide an opportunity for major cost savings.

### What is already known on this topic

1.  Differences in appearance and excipients between branded and generic drug products may contribute to negative perceptions of generic drugs

2.  Patients switching back to branded drug products from authorized generic or generic drug products results in a substantial cost to the healthcare system

3.  Authorized generics are generic drug products manufactured by the branded drug product manufacturer, therefore both drug products have the same active ingredients, appearance, and excipients

### What this study adds

1.  Patients who switched from branded to authorized generic drug products had lower rates of brand switchbacks compared with patients who switched from branded to generic drug products

2.  Interventions to improve patient-provider communication to increase patient awareness regarding similarity between branded and generic drug products in terms of quality, safety, and efficacy may be crucial to prevent brand switchbacks

3.  Consistency in appearance between branded and generic drug products may also help in preventing brand switchbacks
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